drugset / Trial / NCT05483439

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

NCT05483439

Phase 2 Unknown 100 enrolled Shengjing Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety of the combination of traditional herbal medicine for cancer immunotherapy and neoadjuvant therapy versus neoadjuvant therapy in patients with breast cancer.

Timeline

Start
2021-10-20
Primary completion
2023-07-01
Completion
2023-07-01

Drugs

EvaluationDrugModalityDoseRoute
Background Carboplatin Small molecule
Background Cyclophosphamide Other / unclassified
Background Docetaxel Small molecule
Background Epirubicin Small molecule
Background Pertuzumab Monoclonal antibody
Background Trastuzumab Monoclonal antibody

Indications